ArticleEpidemiology and infection2024
Mpox in UK households: estimating secondary attack rates and factors associated with transmission, May-November 2022.
Article in Epidemiology and infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Secondary attack rates after mpox exposure in multiple settings during the 2022-2024 pandemic: a systematic review.BMC infectious diseases · 2026Pooled it
- Global epidemiology, viral evolution, and public health responses: a systematic review on Mpox (1958-2024).Journal of global health · 2025Pooled it
- Skin-to-skin household transmission of mpox from parental wrist lesion to child's gluteal region.BMJ case reports · 2026Article
- Mpox in Europe, 2022-2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy.Viruses · 2026Article
- Genomic, virologic, and epidemiologic surveillance to track intrafamilial Mpox, Brazil.Microbiology spectrum · 2026Article
- Characteristics and Transmission Dynamics of Global Travel-Related Mpox Cases Caused by Clade Ib Monkeypox Virus.Emerging infectious diseases · 2026Article
- The mpox epidemic is not over: Reducing disproportionate burden in Africa and persistent global risk require a sustained response.PLoS medicine · 2026Article
- Uncovering the impact of infection routes on within-host MPXV dynamics: Insights from a mathematical modeling study.PLoS computational biology · 2025Article
- Mpox: current knowledge and understanding-a scoping review.FEMS microbiology reviews · 2025Article
- Targeted vaccination is effective for mpox clade Ib in England despite increased household transmission: Predictions from a modelling study.PLOS global public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
We aimed to estimate the secondary attack rate of mpox among UK household contacts and determine factors associated with transmission to inform public health management of contacts, during the global outbreak in 2022. Information was collected via NHS and public health services and included age, gender, place of residence, setting, and type of contact. Aggregate information was summarized for the UK. Record level data was combined for England, Wales and Northern Ireland, and multivariable logistic regression was used to determine factors associated with transmission. The secondary attack rate among UK household mpox contacts was 4% (60/1 526). Sexual contact with the index case was associated with a 11-fold increase in adjusted odds of becoming a case in England, Wales, and Northern Ireland (95% CI 5.5-22,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.